Maraviroc: a new CCR5 antagonist
Tóm tắt
Từ khóa
Tài liệu tham khảo
Maraviroc Protocol A4001050; Pfizer Pharmaceuticals (2007).
Olson WC, Doshan H, Zhan Cet al.Prolonged coating of CCR5 monoclonal antibody for HIV-1 therapy. Presented at:The 13th Conference of Retroviruses and Opportunistic Infections. Denver, CO, USA, 5–8 February 2006 (Abstract 515).
Saag MS, Jacobson JM, Thompson Met al.Antiviral effects and tolerability of the CCR5 monoclonal antibody PRO 140: a proof of concept study in HIV-infected individuals. Presented at:Programs and Abstracts of the 4th IAS Conference. Sydney, Australia, 22–25 July 2007 (Abstract WESS201).
Abel S, Russell D, Medhurst Cet al.Effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427, 857 in healthy volunteers. Presented at:Programs and Abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1–3 April 2004 (Abstract P5.8).
Muirhead G, Ridgway C, Leahy Det al.A Study to investigate the combined co-administration of P450 CYP3A4 inhibitors and inducers on the pharmacokinetics of the novel CCR5 inhibitor UK-427, 857. Presented at:Program and Abstracts of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK 14–18 November 2004 (Abstract P284).
Muirhead G, Abel S, Russell Det al.An investigation of the effects of atazanavir and ritonavir boosted atazanavir on the pharmacokinetics of the novel CCR5 inhibitor UK-427,857. Presented at:Programs and Abstracts of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14–18 November 2004 (Abstract P283).
Jenkins T, Abel S, Russell Det al.The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist, UK-427, 857, in healthy volunteers. Presented at:Program and Abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1–3 April 2004 (Paper No. P 5.4)
Abel S, Taylor-Worth R, Ridgway Cet al.Effect of boosted tipranavir on the pharmacokinetics of maraviroc (UK-427, 857) in healthy volunteers. Presented at:Programs and Abstracts of the 10th European AIDS Conference. Dublin, Ireland, 17–20 November 2005 (Abstract LBPE4.3/15).
Murihead G, Russell D, Abel Set al.An investigation of the effects of tenofovir on the pharmacokinetics of the novel CCR5 inhibitor UK-427, 857. Presented at:Program and Abstracts of the 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 14–18 November 2004 (Abstract P282).
Andrews E, Glue P, Labadie Ret al.A pharmacokinetic study to evaluate an interaction between maraviroc and raltegravir in healthy adults. Presented at:Program and Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, 25–28 October 2008 (Abstract H-4055).
Saag M, Ive P, Heera Jet al.A multicenter, randomized, double-blind, comparitive trial of a novel ccr5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT Study. Presented at:Program and Abstracts of the 4th IAS Conference. Sydney, Australia, 22–25 July, 2007 (Abstract WESS104).
Lalezari J, Goodrich J, DeJesus Eet al.Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic antiretroviral treatment experienced patients infected with CCR5-tropic HIV-1: 24-week results of a Phase 2b/3 study in the USA and Canada. Presented at:Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007 (Abstract 104bLB).
Lalezari J, Mayer H; for the MOTIVATE study team. Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48 week results of MOTIVATE 1. Presented at:Program and Abstracts of the 47th Interscience Conference Antimicrobial Agents Chemotheray. Chicago, IL, USA, 17–20 September 2007 (Abstract H-718a).
Nelson M, Fatkenheuer G, Konourina Iet al.Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viremic, antiretroviral treatment experienced patients infected with CCR5-tropic (R5) HIv-1 in europe, australia and north america: 24-week results. Presented at:Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25–28 February 2007 (Presentation 104aLB).
Fatkenheuer G, Konourina I, Nelson Met al.Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viraemic, antiretroviral treatment-expereinced pateinst infected with CCR5-tropic (R5) HIV-1 in Europe, Australia and North America (MOTIVATE 2): 48-week results. Presented at:Program and Abstracts of the 11th European AIDS Conference. Madrid, Spain, 24–27 October 2007 (Abstract PS3/5).
Mayer H, Van der Ryst E, Saag Met al.Safety and efficacy of maraviroc (MVC), a novel CCR5 antagonist, when used in combination with optimized background therapy (OBT) for the treatment of antiviral-experienced subjects infected with dual/mixed-tropic HIV-1: 24-week results of a Phase 2b exploratory trial. Presented at:Program and Abstracts of the 16th International AIDS Conference. Toronto, Canada, 13–16 August 2006 (Abstract THLB0215).
Van der Ryst E, Mayer H, Goodrich JMet al.Selective suppression of R5 variants by the novel CCR5 antagonist maraviroc (MVC) is not associated with CD4 cell decline in antiretroviral-experienced patients infected with dual/mixed-tropic HIV-1. Presented at:Program and Abstracts of the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, 12–16 November 2006 (Abstract 286).
Davis J, Hilsden F, Sudworth Det al.A single dose study to investigate the effect of the CCR5 antagonist UK-427, 857 on the QTC interval in healthy subjects. Presented at:Program and Abstracts of the 15th International conference on AIDS. Bangkok, Thailand, 11–16 July 2004 (Abstract TUPEB4605).
Mori J, Mosley M, Lewis Met al.Characterization of maraviroc resistance in patients failing treatment with CCR4- tropic virus in MOTIVATE 1 and MOTIVATE 2. Presented at:Program and Abstracts of the XVI International HIV Drug Resistance Workshop. St. Michael, Barbados, 12–16 June 2007 (Abstract 10).
Mori J, Lewis M, Simpson Pet al.Characterization of maraviroc resistance in patients failing treatment with CCR5-tropic virus in MOTIVATE 1 and MOTIVATE 2 (24 week analysis).European HIV Drug Resistance Workshop. Budapest, Hungary, 26–28 March 2008 (Abstract 51).
Lewis M, Mori J, Simpson Pet al.Changes in V3 loop sequence associated with failure of maraviroc treatment in patients enrolled in the MOTIVATE 1 and 2 trials. Presented at:Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Abstract 871).
Van der Ryst Eet al.Changes in HIV-1 co-receptor tropism for patients participating in the maraviroc MOTIVATE 1 and 2 clinical trials. Presented at:Program and Abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17–20 September 2007 (Abstract H-715).
Tsibris AMN, Gulick RM, Su Zet al.In vivoemergence of HIV-1 resistance to the CCR5-antagonist vicroviroc: findings from ACTG A5211. Presented at:Program and Abstracts of the XVI International HIV Drug Resistance Workshop. St Michael, Barbados, 12–16 June, 2007 (Abstract 13).
Mosley M, Smith-Burchnell C, Mori Jet al.Resistance to the CCR5 antagonist maraviroc is characterised by dose-response curves that display a reduction in maximal inhibition. Presented at:13th Conference on Retroviruses and Opportunistic Infections (CROI 2006). Denver, CO, USA, 4–6 February 2006 (Abstract 598).